Wyeth glaucoma drug in short supply
This article was originally published in Scrip
Executive Summary
Wyethis limiting US sales of its glaucoma treatment Phospholine Iodide, 6.25mg (0.125% echothiophate iodide for ophthalmic solution) owing to a product shortage. In a letter to healthcare providers, Wyeth said it expects to be out of the product in the near future, and the outage may be prolonged owing to a delay in supplies of raw material used to make the ophthalmic. The company has initiated a limited distribution plan restricting sales to current patients only, one bottle per patient. Phospholine Iodide, which received FDA approval in 1960, is indicated for treatment of glaucoma and accommodative esotropia. Glaucoma patients using the drug should be instructed to contact their prescribing physicians to seek alternative therapies.
You may also be interested in...
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.
US FDA Drugs Center Launches Clinical Trial Innovation Hub With Demonstration Projects
CDER’s Center for Clinical Trial Innovation (C3TI) will support innovative clinical trial approaches designed to improve the quality and efficiency of drug development and regulatory decision-making. The initiative includes demonstration projects on Bayesian analyses, selective safety data collection and point-of-care trials.